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I 
ABSTRACT 
Liver X receptors (LXRs) are ligand-activated transcription factors belonging to the 
nuclear receptor (NR) superfamily. Up-to-date, more than 1900 publications have 
established the role of LXRs in cholesterol homeostasis, lipogenesis, glucose 
metabolism, atherosclerosis, proliferation, and inflammation. In this thesis we have 
focused mainly on the role of LXR in proliferation and inflammation. 
In Paper I we studied the role of LXR on the inhibition of proliferation in breast 
cancer cell lines through PI3K/AKT signalling pathway. Phosphorylation of several 
protein kinases in this pathway was reduced upon LXR activation, such as AKT and 
PI3K. Expression of both phosphatases PTEN and PHLPP, which directly regulate 
PI3K product (PIP3) and AKT respectively, was induced by LXR on transcriptional 
and protein levels. Furthermore, we showed that LXRβ was main executer of the anti-
proliferative effect in human MCF7 breast cancer cell line. 
In Paper II we continued the findings of paper I to explore more the role of LXR in 
inhibition of proliferation in human breast cancer cell line in relation to signalling 
pathway. In this study we investigated whether LXR regulates mTOR complex 
pathway in human breast carcinoma cell line. Thus, we identified that activated LXR 
inhibited proliferation of MCF7 cell via mTORC1 by affecting the phosphorylation of 
Raptor at Ser792 and mTOR at Ser2448, and its downstream target p70S6K and 
4EBP1. Our data showed that there was no direct effect of LXR on the 
phosphorylation status of mTORC2. We further identified that LXR stimulation 
induced proliferation of MCF7 cells when Raptor was depleted, suggesting the crucial 
role of Raptor in LXR inhibition of cell proliferation. 
In Paper III we investigated the impact of LXR agonists on triple negative human 
breast cancer using a patient-derived xenograft model. Primary tumors from patients 
were grafted into immune–compromised mice, where the tumour was allowed to 
expand. The primary tumour was then collected and used for subsequent xenografts, 
for generating a large mouse colony, all bearing tumors were shown that maintained 
the characteristics of the original tumour. We found that activation of LXR reduced 
progression of triple negative breast tumors in vivo. Moreover, we showed that LXR 
reduced phosphorylation of AKT at Ser473 residue, decreased expression of the 
proliferation marker Ki67, as well as reduction of both α-SMA (smooth muscle actin) 
and capillary density. The last two are angiogenic markers, thus suggesting a role of 
LXR in regulation of angiogenesis. 
In Paper IV we demonstrated a protective role of LXR in inflammatory bowel 
disease (IBD). We used dextran sodium sulfate (DSS) and 2,4,6-trinitrobenzene 
sulfonic acid (TNBS) to induce colitis in mice. We observed that LXR deficient mice 
showed severe and fast disease progression with slower recovery as well as decreased 
survival rates. In addition, activation of LXR reduced the infiltration of immune cells 
and the expression of inflammatory cytokines, chemokines in the colon epithelium of 
mice. In patients with IBD, expression of both LXRα and LXRβ were significantly 
suppressed in inflamed colon compared with healthy controls. 
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1 INTRODUCTION 
1.1  CANCER  
Cancer is a worldwide-distributed disease. It is the second most frequent disease 
in USA, according to the American Cancer Society, which accounts 1 of every 4 
deaths [2]. WHO, world health organization, has estimated 8.2 million cancer 
related deaths worldwide in 2012 [3]. In Sweden, 64 555 new cases of cancer 
were recorded for 2014 among these breast cancer was the most common among 
women, with 9730 new cases [4]. Lung, prostate, colorectal, stomach, and liver 
cancer are the most common types of cancer in men, while breast, colorectal, 
lung, uterine cervix, and stomach cancer are the most common types of cancer in 
women [5]. 
 
Cancer is a heterogeneous disease with abnormal and uncontrolled growth of 
cells that are able to spread to other parts of the tissues by a process called 
metastatization [6]. Hanahan and Wienberg have provided the principle concepts 
how cancer cells sustain their growth and escape from different anti-tumor 
mechanisms. This concept named the ‘Hallmarks of Cancer’, include sustaining 
proliferative signalling, evading growth suppressors, resisting cell death, 
enabling replicative immortality, inducing angiogenesis, activating invasion and 
metastasis, reprogramming of energy metabolism, and evading immune 
destruction [6]. The reasons why some people develop cancer and others not are 
not well understood but there are many common risk factors that link to cancer 
development. Most of these factors are related to age, lifestyle habits, and the 
environment including: tobacco, alcohol, radiation, obesity, infectious agent, 
hormones, chronic inflammation, diet, immunosuppression, and cancer-causing 
substances [7, 8].  
 
The process of cancer development occurs in various stages, which are mainly 
divided based on the TNM system. The TNM system normally stated as: Tumor 
(T) which refer to how large the primary tumor is and where it is located, while 
Node (N) observes the spreading of the tumor to the lymph node, and 
Metastasis (M) refers to the spreading of the tumor to other parts of the body. 
Based on the TNM staging system, most cancers have four stages: 
 
• Stage 0: Cancer in situ (in place). The cancer has not spread to nearby 
tissues and still located in the place where it started. 
 
• Stage I: The cancer has still not grown deeply to nearby tissues. This is 
called early stage cancers. 
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• Stage II and III: The tumors become larger and grow deeply into the 
nearby tissues and they may have spread to the lymph node, but not to 
other tissues and organs. 
 
• Stage IV: The cancer has spread to other part of the body and this is 
called advanced cancer or metastasis. 
Depending on the cancer stages and types, there are various strategies for cancer 
treatment. The most common cancer treatments are surgery, radiation, and 
chemotherapy but there are also other ways of cancer treatment that include 
targeted or biological therapies, hematopoietic stem cell transplantation, 
angiogenesis inhibitors, cryosurgery and photodynamic therapy. We have to take 
in consideration that every cancer treatment has potential risks and side effects 
and not all forms of treatments are suitable for all patients. 
 
1.2 BREAST CANCER 
Breast cancer is the most widespread malignancy among women and the most 
leading cause of cancer death worldwide. Of all cancer type diagnosed in 
women, breast cancer has the highest incidence rate of 25% and the mortality 
rate reaches 15% [9]. The risk of developing breast cancer increases with certain 
lifestyles (dietary habit, alcohol consumption and low number of children), age, 
obesity, high breast density, hormonal imbalance, exposure to toxins and 
ionizing radiation, and genetic factors. It has been estimated that inherited 
factors account approximately 5-10% of all cases of breast cancer [10]. Mutation 
in BRCA1 and BRCA2 tumor suppressor genes are among the most common 
genetic factors influencing breast cancer with a risk of 60-80% in those affected. 
Mutations in P53 and phosphatase and tension homologue 10 (PTEN) are among 
the rare significant hereditary factors for development of breast cancer [11, 12].  
The breast tissue is mainly made up of two systems, glandular system called 
lobules that can produce milk and thin tubular system called ducts, which carry 
milk from glands to the nipple. Additionally, breast consists of fat, lymph nodes, 
blood vessels and connective tissues. The most common type of breast cancer is 
the mammary ductal carcinoma, but breast cancer also can originate from cells 
of the lobules, so called lobular carcinoma. In a rare situation breast cancer can a 
rise from connective tissue and produce breast cancer sarcoma. Also males can 
develop breast cancer, however it is very rare and principally only ductal 
carcinoma. Based on histological features, stage of the tumors, presence of 
different markers such as estrogen receptor alpha (ERα), progesterone receptor 
(PR) and human epidermal growth factor receptor 2(HER2); breast cancer can 
be classified into the following subgroups [13] Table 1: 
      Introduction                                       Treska S. Hassan  
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Table 1: Subgroups of breast cancers. 
 
 
 
 
Identifying different types of breast cancer based on previous classification 
facilitate the way to diagnose and treat the patients. For example, triple positive 
breast cancer (ERα, PR and HER2 positive) can be targeted by using hormonal 
therapy against ERα, and PR as well as using humanized monoclonal antibody 
against HER2. The triple negative breast cancer (ERα, PR and HER2 negative) 
represents approximately 13% of breast cancer cases. Triple negative breast 
cancer is a basal-like carcinoma and among the most aggressive group and very 
challenging to treat [14]. 
Over the recent decades there have been an improvement in breast cancer 
treatment due to earlier detection, and availability of new therapeutic strategies. 
However breast cancer treatment is still challenging, since treatments are 
complex, affected by side effects, and expensive. Although surgery remains the 
first option and the most successful way of breast cancer treatment, there are also 
another ways with either adjuvant treatment (after surgery) or neoadjuvant 
treatment (before surgery). Chemotherapy, radiotherapy, biological therapy 
(targeted drug therapy), and endocrine therapy are among other options in breast 
cancer treatment [15-17].  
 
1.3 LIVER X RECEPTOR (LXR) 
Liver X receptors (LXRs) are ligand activated transcription factors that belong to 
the nuclear receptor (NR) superfamily. NRs are a large superfamily and regulate 
genes important to various physiological processes in the body such as 
metabolism, adult homeostasis, reproduction, embryonic development and cell 
growth. The natural ligands of NRs are endocrine hormones such as thyroid 
hormones and other small molecules like; fatty acids, cholesterol derivatives, 
retinoic acid, and prostaglandins [18]. Consequently, many NRs are targeted to 
develop drugs against different diseases such as cancer, diabetes, obesity and 
atherosclerosis [19]. For example, targeting androgen receptor (AR) and 
estrogen receptor (ER) for treatment of prostate cancer and breast cancer 
respectively, while thyroid hormone (TR) and peroxisome proliferator-activated 
Subtype ERα PR HER2 
Luminal, A + + - 
Luminal, B + + + 
HER2 overexpression - - + 
Basal-like + + + 
      Introduction                                       Treska S. Hassan  
 4 
receptor (PPAR) ligands are used to treat both hypothyroidism, dyslipidemias, 
and diabetes respectively [18]. 
The NRs consist of 48 members in humans, 49 in mice, and 47 in rat [20]. The 
first classification of the NRs was based on functional and structural features and 
was subdivided into four subfamilies [21, 22] (Table 2). Later, NRs have also 
been subdivided into six superfamilies based on sequence homologies of the 
DNA binding domain (DBD) and the ligand-binding domain (LBD) [23-26]  
NRs consist of five distinctive structural domains (A-F). The N-terminal 
regulatory domain (A/B domain) contains a ligand independent activation 
function 1(AF-1). The conserved DBD (C domain) consists of two zinc fingers 
that bind to the corresponding response element on the DNA. The hinge region 
(D domain) is a flexible region that links DBD to the LBD. The LBD (E domain) 
is responsible for ligand binding, receptor dimerization and ligand dependent 
interaction with various coregulators via activation function 2(AF-2). The AF-2 
dependent interaction is often mediated via a NR-box (LxxLL motif) displayed 
on various coregulators [1]. Some NRs also have a highly variable C-terminal 
region (COOH, F domain) [21, 23] (Figure 1). 
 
Table 2: The nuclear receptor superfamily. The table shows the subdivision of NRs into 
four classes according to the functional and structural features. 
 
 
 
 
 
 
 
 
 
   
 
 
Steroid Receptors 
 (Type I NRs) Non steroid RXR heterodimers (Type II NRs) 
NR Ligands NR Ligands 
GR 
MR 
PR 
AR 
ER 
Glucocorticoid 
Mineralocorticoid 
Progesterone 
Testosterone 
Estrogen 
LXR 
PPAR 
FXR 
PXR 
TR (α and β) 
RAR 
VDR 
CAR 
RXR 
Oxysterols 
Fatty acid 
Bile acid 
Xenobiotics 
Thyroid hormone 
Retinoic acid 
Vitamin D, bile acid 
Xenobiotics 
Retinoic acid 
Dimeric Orphan 
Receptors (Type III NRs) 
Monomeric/Tethered Orphan Receptors  
(Type IV NRs) 
COUP 
HNF-4 
TR (2 and 4) 
TLL 
GCNF 
NGFI-B 
SF-1 
Rev-erb 
ROR 
ERR 
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Figure 1: Functional domains of nuclear receptors. AF1: Activation function 1; DBD: 
DNA binding domain; LBD: Ligand binding domain; AF2: Activation function 2. 
LXRs were initially classified as orphan nuclear receptors because at time of 
discovery no natural ligands were known. Latterly, identification of several 
physiological ligands has adopted these receptors. LXRs generally forms a 
permissive heterodimer with the retinoid X receptor (RXR) and were identified 
in 1994-1995 by screening rat and human liver cDNA library and firstly named 
ubiquitous receptor (UR), orphan receptor 1 (OR-1), RLD-1, NER and RIP-15 
[27-32].  
Up-to-date, more than 1900 publications have established the role of LXRs in 
cholesterol homeostasis, lipogenesis, glucose metabolism, atherosclerosis, 
diabetes, Alzheimer’s disease, proliferation, and inflammation. Two isomers of 
LXRs have been identified in human, LXRα (NR1H3) encoded by a gene 
located on chromosome 11p11.2 and LXRβ (NR1H2) encoded by a gene located 
on chromosome 19q13.3. These two isomers share about 77% identity in their 
DBD and LBD, and are activated by the same ligands. Human LXRβ (460 
amino acids) is ubiquitously expressed, whereas LXRα (447 amino acids) has a 
more restricted expression pattern predominantly in tissues with high metabolic 
rate including liver, kidney, adipose tissue, small intestine and macrophage [33]. 
 
1.3.1 Structural and Functional Organization of LXR 
The LXRs accommodate a canonical NR structure [1, 30]. As mentioned 
previously, LXR function as a permissive heterodimer with RXR and binds to 
specific sequences on the DNA, called LXR response elements (LXREs). 
LXREs consist of two concensus 5´-AGGTCA-3´ sites separated by four 
nucleotides called direct repeat-4 motifs (DR-4). LXR/RXR heterodimer can be 
activated by either LXR ligand, RXR ligands or synergistically by ligands of 
both receptors [28, 30, 34].  
In the absence of ligand, LXR is associated with corepressors such as nuclear 
receptor corepressor (NCoR), silencing mediator for retinoic acid and thyroid 
hormone receptor (SMART), and histone deacetylases (HDACs) at many 
regulatory regions (i.e. enhancer and promoters) and follows the conventional 
coregulator exchange mechanism. Upon ligand binding the corepressor complex 
dissociates and recruitment of coactivators results in activation of target genes 
AF1 NH2- DBD -COOH Hinge AF2 LBD 
NRs  
Ligands 
A/B C D E F 
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expression [35]. In addition to the classical coregulator exchange mechanism 
recent data also suggests an alternative mechanism, a strictly ligand dependent 
recruitment of LXR to target genes [36, 37]. A large number of coregulators 
have been identified that contribute to the NR function. Many of these proteins 
are component of multiple-protein complexes with associated enzymatic 
functions including nucleosome remodeling activity, histone acetyltransferase 
and histone methyltransferase activities, which directly or indirectly recruit core 
transcriptional machinery to the promoter region (Figure 2) [38]. In addition to 
the metabolic activities, LXR also display anti-inflammatory activities via a 
mechanism called transrepression [39, 40]. The mechanism of transrepression by 
LXR will be discussed in further detail below (1.3.5). 
 
 
 
 
 
 
Figure 2. Model of classical transactivation pathway of LXR. Unliganded LXR-RXR 
heterodimer is bound to the DNA via an LXRE together with a corepressor (CoR) 
complex, inhibiting target gene transcription. Ligand binding causes conformational 
changes promoting the release of the CoR complex and recruitment of coactivator 
(CoA), thus facilitating histone modification and chromatin remodeling, leading to the 
transactivation of target gene expression [34]. 
 
1.3.2 LXR ligands 
The LXRs are activated by a specific group of mono-oxidized cholesterol 
derivatives (oxysterol). It is believed that cholesterol itself has no effect on 
LXRs, but their derivatives are the most potent naturally activators of LXRs 
including: 20 (S)-, 22 (R)-, 24 (S)-, 25-, 27-hydroxycholesterol, 24 (S), 25-
epoxycholesterol (abundant in the liver). Importantly, these oxysterols were 
shown to bind and stimulate transcriptional activity of LXRs at a concentration 
within the physiological range [41]. Recently, it has been shown that LXRs can 
be activated by cholic acid (3α, 7α, 12α- trihydroxy-5β-cholan-24-oic acid) in 
the brain [42]. D-glucose, D-glucose-6-phosphate and phytosterols (plant 
sterols), were also reported to be LXR activators [43, 44]. In addition to the 
endogenous and natural ligands, various synthetic potent agonists can activate 
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LXRs. GW3965 [45] and T0901317 [46] are among the most commonly used 
ligands in experimental studies, displaying EC50 values in low nanomolar range 
for both LXRα and LXRβ [47]. Additionally to LXR activation, T0901317 has 
been reported to activate farnesoid X receptor (FXR) [48], pregnane X receptor 
(PXR) [49] and retinoic acid receptor-related orphan receptors (RORs) [50]. 
LXR heterodimerize with RXR and thus can also be activated by RXR ligands 
such as 9-cis retinoic acid [30]. There are other new synthetic agonists available 
that can activate LXRs pathway in specific tissues, known as tissue-selective 
agonists, such as: LXR-623, WYE-672 and GSK9772 [51-53].  
In contrast to LXR agonists, there are only few antagonists known to negatively 
regulate the transcriptional activity of LXR and inhibit the interaction of LXRs 
with coactivators. The natural antagonist geranylgeranyle pyrophosphate and 
GSK2033 (a synthetic antagonist) are reported to inhibit LXR activity [54, 55] 
(Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Structure of LXR ligands and antagonists. Chemical structures of LXR 
endogenous ligands, synthetic ligands, inhibitor and tissue specific agonists [33]. 
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LXRs activity is not only regulated by agonists or antagonists, but also by 
changes in receptor expression. A study has been demonstrated that LXRα but 
not LXRβ receptor expression is controlled by auto-regulatory mechanism. The 
auto-regulation of LXRα is limited to human cell types (macrophage, adipocytes, 
hepatocytes, skin fibroblasts and myocytes) [56]. 
 
1.3.3 LXR and cholesterol metabolism 
Identification of oxysterols as a potent physiological ligand of LXRs pointed out 
the crucial role of this receptor in cholesterol metabolism. LXRs are involved in 
all aspects related to the cholesterol metabolism including regulation of reverse 
cholesterol transport (RCT), conversion of cholesterol to bile acid, and 
cholesterol absorption/excretion in the intestine [57]. RCT is regulated by LXRs 
through control of transcriptional regulation of genes involved in the efflux of 
cholesterol out of the cells, for instance ATP-binding cassette (ABC) including 
ABCA1 and ABCG1 [46, 58]. In the liver, ABCA1 induces cholesterol efflux to 
lipid poor apolipoprotein A1 (ApoA1). This process generates high-density 
lipoproteins (HDL) particles and initiates RCT, while ABCG1 transports 
cholesterol to phospholipid containing acceptors such as HDL [46, 59, 60].  
ABCG5 and ABCG8 are two members of the ABC family responsible for the 
secretion of cholesterol from liver to bile. These two proteins also regulate 
cholesterol absorption by intestine. ABCG5/G8 forms an obligate heterodimer 
and are regulated by LXR [61]. Both cholesterol and phytosterols are absorbed 
by intestinal enterocytes via Niemann Pick C1-like protein (NPC1L1) [62]. 
Activation of LXR by synthetic ligand decreases intestinal expression of 
NPC1L1 and up regulates expression of ABCG5/G8. Cholesterol, but not 
phytosterols is esterified by 1-1-Acyl-Coenzyme A: Cholesterol Acyltransferase 
2 (ACAT2) and incorporate into chylomicrons. Phytosterols remain unesterified 
and are transported back to the intestinal lumen by ABCG5/G8 transporters [63, 
64]. Mutations in either monomers cause β-sitosterolemia, which is characterized 
by hyperabsorption and decrease in biliary excretion of phytosterols [65]. It has 
been shown that ABCA1 is an important factor in HDL biosynthesis in the 
intestine upon LXR activation [33, 66, 67]. Moreover, LXRα activation in mice 
stimulates RCT in intestine and inhibits the intestinal absorption through 
upregulation of ABCG5/G8 and downregulation of NPC1L1, which lead to 
increase in sterol secretion and regulation of cholesterol efflux [61, 68].  
LXR not only influences cholesterol metabolism, but also regulates lipid 
homeostasis and inflammatory responses in the body, especially in macrophage. 
Activation of LXR by synthetic ligands is expected to have a great effect on the 
initiation and development of both atherosclerosis [69, 70] and Alzheimer’s 
disease [71, 72]. Mechanistic studies have shown that upon LXR activation in 
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macrophage, the anti-atherosclerotic effects of LXR are largely attributed to the 
anti-inflammatory effects that are secondary to the effect on cholesterol 
metabolism [34, 73]. 
 
1.3.4 LXR and cancer proliferation 
In the past few years, the antiproliferative effect of LXRs activated by either 
synthetic or natural ligands in vitro and xenograft have been observed in various 
types of cancer such as prostate [74-76], ovarian [77], breast [75, 78, 79], colon 
[80, 81] and glioblastoma carcinoma [82]. These studies not only suggest the 
effect of LXRs on cell proliferation, but also describe the potential mechanisms 
of action. LXRs inhibit proliferation by several mechanisms, for instance 
through regulation of cell cycle genes, regulation of signalling pathways, 
through regulation of metabolic genes (cholesterol metabolism), through 
induction of apoptosis, and/or through a potential mechanisms affecting 
hormone signalling.  
The first report identifying the role of LXR in proliferation was in prostate 
cancer. Activation of LXR using synthetic ligand (TO901317) increased the 
protein levels of cyclin-dependent kinase (CDK) inhibitor (p27) but had no 
effect on the mRNA level. In contrast, the expression levels of S-phase kinase-
associated protein 2(SKP2), a protein that targets p27 for degradation, was 
decreased upon ligand activation that led to inhibition of proliferation in prostate 
cancer cell line [75].  
In ovarian cancer cells and in vascular smooth muscle cells (VSMC) treatment 
with LXR agonist also leads to increased expression of p27, as well as its family 
member p21, which significantly suppresses proliferation and induces apoptosis 
[77, 83]. Independently of the direct effects on the cell cycle, ovarian cancer 
cells proliferate in response to the accumulation of oxidized LDL cholesterol. 
LXR activation by the synthetic ligand TO901317 was shown to inhibit 
proliferation by increasing the cholesterol efflux and by suppressing the 
expression of pro-inflammatory cytokines [84]. In breast cancer cells the 
expression levels of SKP2 are decreased without any effect on p27 and p21 
protein levels [78]. One study on ER-positive breast cancer cell lines treated with 
LXR agonist also showed decrease in the expression of E2F2, a transcription 
factor that regulates cell cycle progression [85]. Furthermore, in leukemic T-cells 
and lymphoblast, induction of LXR with TO901317 or GW3965 inhibit 
proliferation of the cells by preventing cell cycle progression from G1 phase to 
S-phase by alteration in the phosphorylation of Retinoblastoma protein (RB), a 
key regulator of entry to S-phase, without any effects on p27 [86]. In colon 
cancer and pancreatic cancer, SKP2 is downregulated upon LXR activation and 
consequently resulting in disruption of proliferation [87, 88].  
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Interestingly, activation of LXR in pancreatic cancer cells leads to increased 
expression of epidermal growth factor receptor (EGFR) suggesting a crosstalk 
between LXR and growth factor signalling pathways [88], as also shown in 
glioblastoma carcinoma [82]. In glioblastoma, which is one of the most common 
and lethal malignant brain tumors in adults, cells treated with GW3965 inhibit 
EGFR expression through upregulation of ABCA1, cholesterol efflux 
transporter, which regulates cholesterol homeostasis through suppression of 
PI3K/AKT signalling pathway and promotes cell death [82]. Intriguingly, a new 
role of non-transcriptional function of LXR has been addressed in colon cancer 
where LXRβ was shown to induce cell death by pyroptosis through induction of 
Caspase-1 [89]. 
As previously mentioned, LXR inhibit proliferation through several 
mechanisms, for example in prostate cancer suppression of proliferation is not 
just related to the cell cycle genes regulation but also through cholesterol 
depletion from the lipid rafts by induction of expression of ABCG1 that leads to 
an increase in cholesterol efflux that subsequently activates PI3K/AKT 
signalling pathway crucial for cell survival [76]. In another study, cholesterol 
homeostasis in prostate cancer has shown to be regulated by LXR target genes 
ABCA1 and ABCG1, which mediate cholesterol efflux in LNCaP prostate 
cancer cells and consequently lead to lipid deprivation in the cell membrane 
necessary for maintaining of cell growth [90]. 
The correlation between LXR, proliferation and cholesterol homeostasis has also 
been shown in mouse liver regeneration after partial hepatectomy (HP), in which 
part of the liver was removed in order to study the ability of liver to regenerate. 
In HP, the cholesterol level of the liver is increased in response to regeneration 
processes. At the same time, activation of LXR with GW3965 reduced the 
regeneration of liver thus indicating also in this model the importance of LXR in 
cell proliferation [91]. The antiproliferative effects of LXR in certain types of 
cancer cell lines is also related to the expression of lipogenic target genes 
SREBP1 and fatty acid synthase (FASN) [92]. In prostate cancer cell line, 
knockdown of FASN partially suppresses the anti-inflammatory effects of 
liganded LXR and increases expression of suppressor of cytokine signalling 3 
gene (SOCS3), which lead to increase of cell death and decrease of 
proliferation[93], while in breast cancer the knockdown of SREBP1 shows no 
changes of the antiproliferative effect in response to LXR ligand [78]. 
Another mechanism of LXRs to inhibit proliferation is their effects on steroid 
hormone receptors. This mechanism seems to be specific to ER+ breast cancer 
and to prostate cancer associated with AR. The effect of LXR on hormone 
dependent proliferation in ovarian cancer has not been reported [34]. Androgens 
and androgen receptors signalling play an important role in the development of 
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both normal prostate growth and in diseases related to prostate, especially 
prostate cancer. One study has shown that LXR agonist TO901317, but not 
22(R)-hydroxycholesterol and 24(S)-hydroxycholesterol acts as anti-androgenic 
agonist in human prostate cancer cells [94]. Furthermore another study has 
demonstrated that ligand treated LXRα overexpressed mice inhibits AR activity 
by increasing expression of sulfotransferase enzyme 2A1 (SULT2A1) and 
decreasing expression of steroid sulfate [95]. Similarly, LXRs regulate estrogen 
homeostasis in the liver by increasing expression of estrogen sulfotransferase 
(Est or SULT1E1), which consequently suppresses estrogen-dependent breast 
cancer cell proliferation in nude mice [96]. There are also evidence indicating 
that activated LXR suppresses breast cancer cell proliferation through 
inactivation of ER both on protein and transcriptional levels [78, 85]. 
 
1.3.5 LXRs regulate inflammatory responses and immunity 
Recent studies have revealed that LXRs are important factors in innate and 
adaptive immunity and inflammatory response beside their known role in 
metabolism [57]. LXRs and other NRs, such as PPARs, upon ligand activation 
can inhibit the activities of other signal dependent transcription factors such as 
nuclear factor kappa-B (NFκB) and activator protein-1 (AP-1) through a 
mechanism called transrepression. This mechanism includes protein-protein 
interaction with the coregulator proteins and prevents the transcription of the 
target genes [97].  
LXRs inhibit signal dependent activation of several inflammatory target genes 
by a transrepression mechanism (Figure 4). Upon ligand binding, LXR 
undergoes SUMOylation, which is a posttranslational modification, by 
conjugation of small ubiquitin-related modifier (SUMO 2 or 3) molecules to 
lysine residues at LXR in the LBD by E3 ligases. Subsequently, SUMOylated 
LXRs, upon docking, prevents the release of corepressors at several 
inflammatory response genes and inhibits the transcription [40, 98].  
Tontonoz and colleagues were the first to demonstrate the link between the anti-
inflammatory actions of LXR and the cholesterol metabolism. In response to 
inflammatory signals mediated by bacterial lipopolysaccharide (LPS), tumor 
necrosis factor α (TNFα), and interleukin 1β (IL-1β) in macrophage, activation 
of LXRs inhibit expression of inflammatory genes such as interleukin 6 (IL-6), 
inducible nitric oxide synthase (iNOS), matrix metallopeptidase 9 (MMP-9), and 
cyclooxygenase 2 (COS-2). Additionally, upon ligand binding, the expressions 
of LXRs target genes (ABCA1 and ABCG1) are increased in macrophage 
stimulated with inflammatory signals, connecting the innate immunity and 
cholesterol metabolism regulated by LXRs [73, 99].  
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Figure 4. Anti-inflammatory transrepression by NRs [100]. 
Protecting macrophage from apoptosis by LXRs was another finding that 
showed the anti-inflammatory action of LXRs. LXRα-deficient mice are 
susceptible to bacterial infection subsequently accelerates macrophage cell 
death. Activation of LXR by synthetic ligands induces expression of several 
antiapoptotic factors, inhibits other pro-apoptotic factors, and reduces this 
phenomenon [101]. 
In addition to anti-inflammatory activities, LXRs also display immune 
regulatory functions. LXRs activated with GW3965 and TO901317 inhibit LPS 
induced neutrophil infiltration in the lung airway and reduce cytokine production 
in primary human and rodent alveolar macrophages [102, 103]. Several in vivo 
studies have demonstrated the role of LXRs in immune response triggered by 
pathogens in the host. For example, in mice infected with Klebsiella pneumonia, 
the mortality rate is increased when LXR is activated with TO901317 [103], 
while LXRα-deficient mice infected with Mycobacterium tuberculosis show 
increased susceptibility to infection and reduced neutrophil response compared 
with wild type mice [104]. On the other hand, LXR deficient mice exhibit more 
resistance to infection with the protozoan parasite Leishmania chagasi/infantum 
[105].  
It appears that activation of LXRs inhibits the inflammatory response in 
ulcerative colitis, which is a type of inflammatory bowel diseases (IBD), and 
even in colon cancer [106]. The molecular mechanisms behind the pathogenesis 
of IBD are not well understood, but evidently it causes deregulation of the 
inflammatory response in small and large intestine. Besides the known 
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components of the inflammatory response, few factors have been reported to 
contribute in the initiation and progression of IBD including environmental 
factors, the luminal flora and genetic predisposition [107]. Moreover, studies 
have shown that increased permeability of the epithelial layer to some extent 
might contribute to the progress of IBD [108, 109]. We have recently reported 
that both LXRα and LXRβ have anti-inflammatory roles in suppression of 
various inflammatory mediators in the colon [106]. 
Important immunomodulatory properties of LXRs have been described in 
various cell types including monocytes, macrophage, T and B cells, skin, 
dendritic cells, brain, muscle, liver, bone, and pancreas [33, 110]. Interestingly, 
the role of LXRs in antigen presenting dendritic cells (DC) and T cells provides 
evidence that link LXR to both adaptive and innate immune response. One study 
suggests that LXR inhibit the ability of DC to activate the adaptive immune 
response via T-cells through reduced expression of inflammatory genes 
associated to maturation and migration of DC in the lymph nodes [111]. But, 
other studies suggest that LXRs induce expression of other pro-inflammatory 
markers that supports maturation and DCs function and induce T-cell 
proliferation [112]. Therefore, the above findings reveal divergent data that 
correlate LXRs with DCs. 
LXRs, especially LXRβ, show anti-inflammatory response in the liver, where 
they inhibit acute phase response (APR) [98]. APR is a systemic change that 
associated with the release of acute phase proteins in response to inflammatory 
stimuli [113]. The anti-inflammatory responses of LXRs are further reported in 
various immune related tissues and diseases including: skin diseases, arthritis, 
and neurodegenerative diseases such as multiple sclerosis, Parkinson’s disease 
and Alzheimer’s disease [72, 114-118]. Also, it has been shown that LXRs 
decrease graft versus-host inflammatory reactions and suppresses the chronic 
damage allograft in rat kidney [119].  
 
1.4 PI3K/AKT/MTOR SIGNALLING PATHWAY 
1.4.1 Normal PI3K/AKT/mTOR signalling cascade  
Receptor tyrosine kinases (RTKs) are cell surface receptors that are activated by 
binding of growth factors such as epidermal growth factor (EGF), insulin like 
growth factor (IGF-1), cytokines, and integrin [120]. They in turn activate 
phosphoinositide 3-kinases (PI3Ks). PI3K is involved in various cellular 
processes such as cell proliferation, growth, motility, survival and angiogenesis 
[121, 122] (Figure 5). 
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Figure 5: Schematic representation of PI3K/AKT/mTOR signalling pathway. Illustration 
reproduced by the courtesy of ROCKLAND antibodies and assays (www.rockland-
inc.com) with slight modification. 
PI3Ks is a family of kinases that consists of several classes and subclasses 
divided according to their structure, tissue distribution, substrate affinity 
activation and function [123]. The class IA is the most abundant and well studied 
in term of signal transduction. PI3Ks also play a central role in the pathogenesis 
of cancer. PI3Ks are heterodimeric lipid kinases composed by two-separated 
regulatory (p85) and catalytic (p110) subunit. The regulatory subunits include 
p85α, p85β, and p85γ that are encoded by PIK3R1, PIK3R2, and PIK3R3 genes, 
respectively. The catalytic subunits are p110α, p110β, p110γ, and p110δ that are 
encoded by PIK3CA, PIK3CB, PIK3CG, and PIK3CD genes, respectively [124-
126]. The regulatory subunits bind directly to RTK, which mediate its 
translocation to the plasma membrane where the PI3K is activated. The 
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regulatory subunits also protect the catalytic subunit from enzymatic degradation 
[127]. Upon activation, PI3K phosphorylates phosphatidylinositol 4,5 
diphosphate (PIP2) and yields the biologically active second messenger 
phosphatidylinositol 3,4,5 triphosphate (PIP3). PIP3 changes its cellular 
localization and undergoes conformational changes, leading to the recruitment of 
3´-phosphoinositide-dependent kinase 1(PDK1) and protein kinase B 
(PKB/AKT) to the cell membrane. Afterwards, activated PDK1 phosphorylates 
AKT, which in turn leads to the phosphorylation and activation of the 
downstream signalling pathways [128]. PI3K is negatively regulated by 
dephosphorylation to its inactive lipid state (PIP2) by the tumor suppressor 
protein phosphatase and tensin homologue deleted on chromosome 10 (PTEN) 
[129, 130]. 
AKT is a serine/threonine kinase and plays a key role in the regulation of various 
molecular functions such as cell cycle progression, apoptosis, transcription and 
translation [131]. There are three isoforms of AKT/PKB proteins encoded by 
three different genes: AKT1/PKBα, AKT2/PKBβ, and AKT3/PKBγ. They share 
around 80% identity in their structure and are similar to the members of AGC 
kinase family (cyclic AMP dependent-protein kinase, cyclic GMP dependent–
protein kinase, and protein kinase C) [132-134]. AKT protein consists of the 
amino terminal pleckstrin homology (PH) domain, the central kinase domain 
(the site for substrate residues), and the hydrophobic carboxy terminal regulatory 
domain. The PH domain is one of the key component by which AKT gets 
activated by PI3K. The AKT isomers are activated by very similar mechanisms 
and are differently expressed in tissues. AKT1 is evenly distributed in all tissues 
whereas AKT2 is expressed in many metabolically active tissues such as liver, 
heart and skeletal muscle. AKT3 has a very restricted distribution; it is highly 
expressed in nervous tissues and testis [134, 135]. Recently, AKT3 has been 
detected in breast tissue [136]. 
When AKT is recruited to the plasma membrane, it is partially activated through 
phosphorylation by PDK1 at threonine 308 (Thr308) in the activation loop of the 
central kinase domain. Moreover, another phosphorylation at serine 473 
(Ser473) in the hydrophobic domain is necessary to get AKT fully activated. 
Phosphorylation of AKT at Ser473 is performed by various kinases including: 
mammalian target of rapamycin 2 (mTORC2), integrin-linked kinase (ILK) and 
by AKT itself due to auto-phosphorylation [137]. Partial activation of AKT at 
Thr308 is enough to activate other AKT downstream targets, such as the 
mammalian target of rapamycin 1 (mTORC1) [138-142]. Two tumor suppressor 
proteins, the PH domain and the leucine-rich repeat protein phosphatase 
(PHLPP) and the protein phosphatase 2A (PP2A) negatively regulate AKT at 
Ser473 and Thr308 residues respectively, due to direct dephosphorylation. When 
AKT is activated, it translocates to different areas in the cytoplasm or nucleus to 
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mediate various phosphorylations on the key substrate and promotes different 
cellular effects [143-145]. 
AKT phosphorylates many substrates based on the consensus motif containing 
the amino acid sequence RXRXXS/T [132]. Some of these substrates are cell 
cycle-related proteins such as glycogen synthase kinase 3 (GSK-3), p21, and 
p27, whereas others are apoptotic proteins such as mouse double minute 2 
homolog (MDM2), forkhead box O3 (FOXO3), Caspase and B-cell lymphoma 
2-associated death promoter (BAD). AKT also regulates proteins important for 
angiogenesis and inflammatory signalling such as eNOS and NFκB. Activation 
of AKT is necessary in many processes related to the cell integrity, glycolysis, 
and tumorigenesis [146]. Another major downstream substrate of AKT is 
mTORC1 that is crucial in protein synthesis, autophagy and cell survival [126].  
mTOR is a serine/threonine kinase, which belongs to PI3K related kinase family. 
mTOR is 289 kDa protein that forms two distinct multi-protein complexes: 
mTORC1 and mTORC2. The two mTOR complexes are regulated differently 
and they show different sensitivities to rapamycin. mTORC1 functions as 
downstream target of AKT, while mTORC2 is known to be upstream regulator 
of AKT activation [147-149]. mTOR signalling is commonly regulated by 
oncogenes and tumor suppressor proteins such as Ras, Raf, and PTEN [150]. 
mTORC1, the rapamycin sensitive complex, consists of at least five subunits: 
mTOR, (catalytic subunit of the complex); Raptor (regulatory-associated protein 
on mTOR); mLST8 or GβL (lethal with Serc13 protein 8); PRAS40 (proline-rich 
AKT substrate 40 kDa); and Deptor (DEP domain-containing mTOR interacting 
protein). Raptor positively regulates mTORC1 activity and directs the complex 
toward the substrates whereas PRAS40 and Deptor are known as negative 
regulator of mTORC1 [151, 152]. AKT activates mTORC1 at Ser2448 residues 
indirectly by Rheb-GTP activation and through PRAS40 inhibition. Rheb-GTP 
is induced through inhibition of TSC1/2 complex mediated by AKT [153, 154]. 
When activated, mTORC1 phosphorylates two downstream effectors that play a 
role in the regulation of protein synthesis and translation, namely p70 ribosomal 
protein S6 kinase (p70S6K1 or S6K1) and the eukaryotic translation initiation 
factor 4E-binding protein (4EBP1) [147].  
S6K1 is the main downstream effector of mTORC1. It can also be activated 
independently on mTORC1 by other signalling pathways such as PDK1 and 
MAPK but at different phosphorylation sites. Phosphorylation of S6K1 at 
Thr389 in the C-terminal hydrophobic domain by mTORC1 is the main target in 
ribosomal protein synthesis [155, 156]. S6K by a negative feedback mechanism 
phosphorylates and inhibits insulin receptor signalling 1(IRS1) [157] and Rictor 
(mTORC2 component), leading to the subsequent inhibition of mTORC2 [158].  
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4EBP1 is another well-characterized downstream target of mTORC1, which 
inhibits initiation of protein translation by binding and inactivating the 
eukaryotic translation initiation factor 4F (elF4E). When elF4E is released, the 
transcriptional level on mRNA of 7-methylguanine caps is increased. The 
inhibition of mTORC1 by rapamycin also causes dephosphorylation of 4EBP1 
and prevents protein translation [131, 159]. 
mTORC2, the rapamycin insensitive complex, consists of at least six proteins 
subunits: mTOR, rapamycin insensitive companion of mTOR (Rictor), 
mammalian stress activated protein kinase interacting protein (mSIN1), protein 
observed with rictor-1 (Protor-1), mLST8, and Deptor. Little information is 
available about mTORC2 structure, components, upstream signal integration and 
downstream targets. But it has been shown that knockout of mTORC2 in mice 
causes early lethality in the embryo [155, 160]. There is no specific inhibitor 
available for mTORC2 so far, and many researchers are trying to identify them. 
Rictor is the core protein for the mTORC2 catalytic activity and recruits the 
complex toward the substrate as Raptor does in mTORC1. mSIN1, which binds 
to Rictor, is an important mTORC2 subunit because it helps in stabilizing the 
complex and is responsible to direct the complex toward AKT. Protor-1 binds 
with Rictor and its function is unknown. mLS8 is necessary for complex stability 
[154]. 
mTORC2 can be activated by the same growth factors and cytokines that 
activate PI3K but by unknown mechanisms [161]. Another evidence suggests a 
possible link between the two complexes that may lead to activation and 
phosphorylation of mTORC2 at Ser2481 residues [162]. mTORC2 regulates 
mTORC1 activity through AKT-TSC1/2 pathway, and in turn mTORC1 controls 
mTORC2 activity through docking with proteins that could be synthesized by 
their downstream target S6K1 [141, 155, 158]. Activated mTORC2, beside AKT 
phosphorylation at Ser473 residue, also phosphorylates and activates other 
downstream targets, such as protein kinase Cα (PKCα) and the serum-and 
glucocorticoid-regulated kinase-1 (SGK1) [163, 164]. 
PKCα is a member of serine/threonine protein kinases and is activated by 
mTORC2, even if the exact mechanism is unknown. However, studies have 
shown that mTORC2 activation results in the stabilization of PKCα protein by 
direct PKCα phosphorylation at Ser657 residue. Like P70S6K, PKCα can also 
be phosphorylated by PDK1. Additionally, PKCα is activated by calcium and the 
second messenger diacylglycerol (DAG) [165]. 
SGK1 is another target of mTORC2 activated by growth factors and regulated 
by mTORC2 that lead to SGK1 phosphorylation at Ser422 residues, which is 
involved in growth and sodium transport through plasma membrane [152, 166]. 
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1.4.2 PTEN and PHLPP 
The tumor suppressor protein PTEN is a well-characterized lipid phosphatase 
that regulates various cellular processes including survival, proliferation, energy 
metabolism and cellular architecture by inhibition of PI3K/AKT/mTOR pathway 
[129]. The structure of PTEN includes several features not observed in other 
protein phosphatases. It consists of 403 amino acids and it is structured into five 
functional domains: PIP2 binding domain (PBD), phosphatase domain (is the 
site of PIP2 binding capacity), C2 domain, carboxy terminal tail, and PDZ 
domain. Phosphatase and C2 domain are required for PTEN activity [167, 168]. 
Some reports suggest the importance of the carboxy terminal region of PTEN for 
the regulation of its binding capacity and its membrane recruitment [168, 169].  
PTEN has a double phosphatase activity on both lipids and proteins. The main 
lipid substrate is PIP3 [170], while protein phosphatase activity regulates cell 
migration by dephosphorylation of focal adhesion kinase (FAK), Src homology 
2 domain containing protein (Shc), platelet derived growth factor receptor 
(PDGFR) and PTEN itself [171]. PTEN converts PIP3 to PIP2 through removing 
the phosphatase group at 3-position of the inositol sugar ring of PIP3 [172]. 
PTEN can regulate protein activity at post-translational and transcriptional level 
by protein-protein interaction and/or by mediating translocation to different cell 
organelles. At the transcriptional level, PTEN has been shown to positively 
regulate EGFR, PPARγ, and p53 [171, 173-175]. At the post-translational level, 
PTEN regulates proteins by different mechanisms: phosphorylation, acetylation, 
and oxidation, all of them leading to PTEN inactivation. PTEN remains 
phosphorylated and inactive in most of the normal cell types; it becomes 
activated when dephosphorylated. The phosphorylated PTEN remains in the 
cytoplasm, but the activated dephosphorylated form it is recruited to the plasma 
membrane to access its substrate [176, 177].  
Another tumor suppressor protein that regulate PI3K/AKT/mTOR pathway is 
PHLPP. PHLPP is a novel serine/threonine phosphatase that belongs to protein 
phosphatase 2C family (PP2C) [178]. PHLPP directly dephosphorylates AKT 
and PKC on their hydrophobic motif resulting in the inhibition of the kinase 
activity, triggering apoptosis and suppressing tumor growth [179-181]. The two 
isomers of PHLPP, PHLPP1 and PHLPP2 are shown to dephosphorylate both 
AKT2 and AKT1 at Ser473 respectively. The dephosphorylation function of 
AKT by PHLPP is mainly depending on the PDZ binding domain [143]. Both 
isomers are present in the cytoplasm, nucleus and plasma membrane. They have 
similar structure consisting of various domains: the amino terminal PH domain, 
leucine-rich repeat region (LRR), PP2C phosphatase domain, and a C-terminal 
PDZ-binding motif [182]. Moreover, PHILPP dephosphorylates PKC resulting 
in the destabilization of the protein, thus leading to its degradation [181, 183].  
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Further studies have shown that PHLPP directly dephosphorylates S6K1, the 
downstream target of mTORC1 as part of a negative feedback loop and deletion 
of PHLPP results in the activation of S6K1 [184, 185]. Another substrate of 
PHLPP is mammalian sterile 20-like kinase 1(MST-1). PHLPP directly 
dephosphorylates MST-1 at Thr387 residue that is required to regulate MAPK 
pathway leading to activation of the downstream signalling effectors, namely 
p38 and JNK, and subsequently to stimulation of apoptosis [186]. 
 
1.4.3 Alteration of PI3K/AKT/mTOR pathway in cancer 
The PI3K/AKT/mTOR pathway is a prototypic survival pathway that is 
constitutively activated in many types of cancer such as colon, pancreas, ovarian, 
breast and glioblastomas [82]. Alteration of signals from upstream membrane 
RTK or signals generated directly by PI3K/AKT/mTOR pathway may lead to 
uncontrolled cellular proliferation, tumour progression, metastasis and resistance 
to drug treatment [120, 187, 188]. Mechanisms of activation include mutation 
(germline and somatic mutation), overexpression, amplification, hyper-
activation, methylation, and aberrant splicing [131, 189]. It is well known that 
hyper-activation of RTK results in several types of cancers. These can be caused 
by either overexpression of the growth factor ligands, such as insulin like growth 
factor-1/2 (IGF-1/2) and epidermal growth factor (EGF) or by 
amplification/overexpression of the receptor themselves such as IGFR and 
EGFR, which lead to activation of PI3K/AKT/mTOR signalling. These events 
have been implicated in tumor progression and invasion [190, 191] 
Amplification of PI3K gene is the major alteration in the signal transduction in 
tumors, and this is confirmed in ovarian and cervical cancer [192, 193]. Also 
mutations of PIK3A gene are frequently occurring in several cancers, such as 
breast, colon and ovarian cancer. PIK3A mutations lead to PIP3 accumulation 
and hyper-phosphorylation of AKT and its downstream targets. This results in 
several phenotype changes, including uncontrolled cell proliferation, reduced 
apoptosis, and malignant transformation [194]. PI3Ks also regulate integrins 
related to cell motility in normal and cancerous status. In breast cancer PI3K is 
induced upon integrin ligation, promoting formation of lamellae and invasion 
[195].  
Loss of PTEN due to either mutations, gene deletion or promoter methylation 
leads to constitutively hyperactivation of all PI3K downstream effectors such as 
AKT, PDK1 and mTOR, as can be observed in many primary and metastatic 
human cancers [196, 197]. 
AKT deregulation does not only determine the increase in its protein level, but 
also leads to constitutively increase in its activity. Constitutively active AKT can 
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be seen in various types of cancers, including breast cancer, and is related to bad 
prognostic outcome [198]. A mutated AKT1 can be seen in gastric carcinoma, 
while AKT2 gene amplification is demonstrated in breast, ovarian, pancreas and 
stomach cancer [199]. Activation of AKT3 is found in estrogen receptor-
deficient breast cancer, triple negative breast cancer, and androgen-insensitive 
prostate cancer [136, 200].  
Alterations in the downstream substrates of AKT have been shown to correlate 
with relapse, metastasis, poor prognosis, and relevant mortality. TSC1/2, which 
regulates mTOR, undergoes hypermethylation and leads to activation of mTOR 
in several kind of cancers [201]. Hyperactivation of mTOR itself is common in 
many types of cancer. mTOR is activated by a mutation that cause cell cycle 
progression and resistance to amino acid depletion [202]. The other two effectors 
of mTOR, namely S6K1 and 4EBP1, are thought to be altered and activated in 
different kind of cancers. Their activation is associated with aggressiveness of 
the cancer phenotype, malignant transformation, and/or progression [196, 203].  
Reduced expression of PHLPP1 or PHLPP2 has been associated with a wide 
spectrum of cancer diseases including prostate cancer [204], breast cancer [205], 
glioblastoma cancer [206], colon cancer [207] and melanoma [208]. Loss of 
PHLPP at both mRNA and protein levels has been associated with progression 
in cell proliferation, whereas overexpression of PHLPP is largely responsible for 
the inhibition of cell growth [207]. 
Nowadays, many researchers are focusing their attention on the study of 
signalling pathways in order to find out possible new therapeutic targets. 
Targeting of PI3K/AKT/mTOR signalling cascade with different anticancer 
drugs may lead to decrease of the progression and diffusion of different kind of 
cancers. Nevertheless, the complexity of this pathway, the crosstalk with other 
alternative cascades, and the presence of feedback loops have created some 
difficulties to identify the specific targets for the different type of cancers. 
However, during the last two decades intensive studies are trying to find out 
novel therapeutic strategies of targeting PI3K/AKT/mTOR pathway in cancer 
patients. 
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1.4.4 LXR and PI3K/AKT/mTOR pathway 
The PI3K/AKT/mTOR is frequently activated in human cancers [126]. As 
mentioned earlier, mechanisms of activation of this pathway includes loss of 
tumor suppressor PTEN function, ampliﬁcation/mutation of PI3K or AKT, 
activation of growth factor receptors and/or exposure to carcinogens [79]. 
Activation of LXR by synthetic ligands such as T0901317 can repress growth of 
human prostatic cell lines in vitro and in vivo [76]. This event resulted in the 
induction of apoptosis after disruption of lipid rafts due to AKT 
dephosphorylation [209]. It has been shown that LXR potentially induces cell 
death in glioblastoma, both in vitro and in vivo by decreasing LDLR protein 
expression and increasing ABCA1-dependent cholesterol efflux transporter via 
PI3K/AKT/mTOR signalling [210]. It has further been shown that activated 
LXR significantly reduces the survival rate in breast cancer due to inactivation of 
the PI3K/AKT/mTOR pathway induced by IGF1 [79]. Recent evidences suggest 
that mTORC1 is also involved in LXR-mediated transcription of lipogenic gene 
including induction of SREBP1c, FAS and acetyl-CoA carboxylase (ACC) in 
liver from mice subjected to a high fat diet [211, 212]. There are very few 
mechanistic studies on how LXRs regulate PI3K/AKT/mTOR pathway, 
especially in cancer. 
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2 AIM OF THE STUDY 
2.1 GENERAL AIM 
The general aims of this study was to investigate the role of LXR in breast cancer 
proliferation in relation to the major signalling pathways and to investigate the role of 
LXR in the inhibition of inflammation in colon. 
2.2 SPECIFIC AIMS 
• To point out the role of PI3K/AKT signalling pathway in the 
antiproliferative effect of LXR signalling in breast cancer cells. (Paper I) 
 
• To investigate whether LXR pathway and mTOR complex interact in 
human breast cell carcinoma. (Paper II) 
 
• To study the impact of LXR on triple negative human breast cancer using a 
patient derived xenograft model. (Paper III) 
 
• To characterize the role of LXRs in colon of mice using a DSS- and TNBS- 
induced colitis model. (Paper IV) 
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3 METHODOLOGY 
3.1 CELL LINES 
Different cell lines were used in this thesis. MCF7 and MDA-MB-231 (human breast 
cancer cell lines), HuH7 (human liver cancer cell line), SW480 and Colo205 (human 
colorectal adenocarcinoma). The cell lines were purchased from American Type 
Culture Collections (ATCC). Cells were grown in different growth media and 
supplemented with different concentrations of fetal bovine serum (FBS) and 
Penicillin/Streptomycin antibiotics (PEST) and were kept in 5% CO2 humidified 
atmosphere at 37°C. 
 
3.2  LABORATORY ANIMALS AND TUMOR GRAFTING 
3.2.1 Animal experiments 
C57B1/6J female mice were used in paper IV. The experimental protocols were 
approved by the Stockholm south ethical committee-Huddinge, according to the 
guidelines of the Swedish National Board of Laboratory Animals at Karolinska 
Institutet, (permit numbers S97-09, S98-11, S148-11, S67-13). Dextran sodium sulfate 
(DSS) and 2,4,6-trinitrobenzene sulfonic acid (TNBS) were used to induce colitis in 
mice [213]. Furthermore, LXR synthetic agonist (GW3965) was used in order to 
elucidate the molecular mechanism underlying the anti-inflammatory action of LXR. 
 
3.2.2 Patient derived xenograft model (PDX) 
Immunocompromised SCID mice were used in paper III and kept under pathogen-free 
conditions, at constant temperature (21.5 ± 0.5 °C) and humidity (55 ± 5%), 20 air-
changes/hr and a 12 h light/dark cycle. Patient-derived triple negative breast cancer 
tumors with a size of 1-2mm3 were grafted into small pockets created in mammary fat 
pads of the mice. After expanding, the tumors were collected and used for subsequent 
xenografts to generate a large mouse colony (Figure 6). In order to study the role of 
LXR in tumor progressions, mice were treated with varying concentration of 
GW3965. After the end point of the experiments, the tumor tissues were collected for 
subsequent analysis. All procedures and experiments involving animals were 
approved by The National Animal Research Authority in Norway (permit number 
5806), and were conducted according to the European Convention for the Protection 
of Vertebrates used for Scientific Purposes.  
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 Figure 6: Workflow of the xenograft model. 
 
3.3  ANTIBODY BASED TECHNIQUES 
3.3.1 Western blotting 
Western blotting is a widely used semi-quantitative technique in cell and molecular 
biology. Western blotting was first introduced by Towbin and colleagues in 1979 
[214]. The principle of this technique is to separate proteins in a mixture depending on 
the size. In this thesis we have focused on phosphorylated proteins. In brief, we 
homogenized the cells or tissue in lysis buffer made fresh and containing a cocktail of 
protease inhibitors and phosphatase inhibitors. As soon as lysis occurs, proteolysis, 
dephosphorylation and denaturation begin. These events can be tremendously slowed 
down if samples are kept on ice or at 4°C at all times and appropriate inhibitors are 
added fresh to the lysis buffer. The details of the method regarding the using of the 
buffers, gels, antibodies, and detection systems are described in each paper of this 
thesis. 
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3.3.2 Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA (also called Enzyme Immunoassay EIA) is a plate-based technique used to 
measure the concentrations of a specific substance in solution such as peptides, 
proteins, hormones and antibodies. The principle of ELISA is based on the use of an 
enzyme linked to an antibody or antigen as a marker for the detection of a specific 
protein. It is very simple, quick and sensitive method. However ELISA has some 
disadvantages. False positive are often reported due to nonspecific reactions with 
samples or cross reactivity. We have used monoclonal antibodies, in order to reduce 
the risk for cross reactivity (paper II and paper IV). 
 
3.3.3 Immunohistochemistry (IHC)  
We have used immunohistochemistry method in paper III and paper IV. IHC is a very 
efficient and commonly used laboratory technique based on detection of antigens 
(proteins) in cells of the tissue sections by binding with specific antibodies tagged 
with visible marker. IHC is very important technique for the identification and 
visualization of the distribution and localization of various cellular components 
especially for cancer. The samples can be viewed either by light or fluorescence 
microscopy. 
 
3.3.4 Isolation of immune cells and flow cytometry 
Flow cytometry is a laser-based technique used in analytical cell biology to count and 
profile cells in a heterogeneous mixture containing live cells. Flow cytometry 
technology is applied in cell counting, cell sorting, biomarker detection and protein 
engineering. In this thesis we have used fluorescence-activated cell sorting (FACS) 
analysis to study different populations of immune cells from lamina propria of the 
mice colon. FACS is a derivative of flow cytometry and is used to sort the cells in a 
heterogeneous mixture into different population by using antibodies tagged with a 
fluorescence dyes. 
The isolation of lamina propria immune cells from the colon in this study was 
performed as previously described by Weigmann and colleague [215] . Briefly, the 
colon was removed from the mice and opened longitudinally and dissected into 1 cm 
pieces. After several washings and digestion steps, the isolated immune cells were 
incubated with different antibodies labeled with fluorescence dye and analyzed by 
flow cytometry using a FACS calibur (BD Bioscience). 
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3.4 QUANTITATIVE POLYMERASE CHAIN REACTION  
 SYBR Green based quantitative Polymerase Chain Reaction (qPCR) was used to 
measure mRNA expression level in a real time. It also called real time PCR because 
the amplification of DNA with PCR is monitored in real time. For qPCR, total RNA 
from cells or tissues was extracted and reverse transcribed into cDNA and analyzed 
using gene-specific primers. The specificity of the primers must be thoroughly tested 
by melting curve analysis in order to get a single PCR product. Endogenous control 
genes were used to normalize the data. Relative gene expression quantifications were 
identified based on the comparative threshold cycle method normalized with 
housekeeping genes.  
 
3.5 CELL PROLIFERATION AND VIABILITY ASSAY 
Various types of assays are available to identify proliferations and viability cells. The 
simplest method to examine cell viability is by monitoring the number of cells 
overtime and counting the number of dividing cells in vitro. Utilizing this concept, we 
used Countess™ automated cell counter from Life Technologies with trypan blue dye, 
which selectively stain dead cells. By counting both stained and non-stained cells we 
can identify the percentage and absolute numbers of viable cells, to investigation the 
cell response after treatment. 
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4 RESULTS AND DISCUSSIONS 
4.1 PAPER I 
LXR Inhibits Proliferation of Human Breast Cancer Cells Through The 
PI3K/AKT Pathway 
It has been demonstrated in many studies that LXRs activation inhibit 
proliferation of tumor growth in different types of cancers including breast, 
colon, prostate, glioblastoma and ovarian cancer [74, 76-78, 82]. The anti-
proliferative functions of LXRs in various models were through various 
mechanisms. Our previous studies in breast and colon cancers have shown that 
LXRs inhibit proliferation through regulation of genes controlling cell cycle such 
as p27, SKP2 and RB [78, 81]. In this study, we showed that activation of LXRs 
with specific synthetic ligands GW3965 reduced the proliferation of breast 
(MCF7) and colon (SW480) cancer cell lines. This reduction was associated 
with the inhibition of the PI3K/AKT signalling activity by decreasing 
phosphorylation of various proteins of this pathway such as AKT on Ser473 
residue. It is well known that PI3K/AKT pathway is prototypic surviving 
pathway that controls various cell physiology such as proliferation, apoptosis, 
protein synthesis and cell survival, and this pathway is activated in various kinds 
of cancer [216]. In the previous studies, it has been shown that loss of tumor 
suppressor proteins PTEN and PHLPP on both mRNA and protein levels are 
associated with progression in various cell processes including cell survival and 
proliferation. On the other hand, overexpression of PTEN and PHLPP seems to 
be largely responsible for inhibition of cell growth due to the activation of 
PI3K/AKT signalling [129, 207]. Interestingly, in this study we found that LXRs 
decreased the level of PIP3 and increased the expression of both PTEN and 
PHLPP.  
Taken together we found that the LXRs-mediated anti-proliferative effects in 
breast cancer cell line were through different molecular mechanisms including: 
1) induction of processes that inhibit degradation of PIP3, 2) suppression of 
processes that generate PIP3, and (3) suppression the phosphorylation of AKT 
by PHLPP (Figure 7). Furthermore, we found a big difference between our 
recent study in breast cancer (Paper I) and previous studies performed on 
prostate cancer and glioblastoma, mainly that the anti-proliferative effects of 
LXR seem to be mediated by PI3K/AKT signalling pathway. In prostate cancer 
cell line (LNCap), LXR reduced proliferation of the cells through disruption of 
lipid raft cell membrane by inducing cholesterol efflux via expressing of ABCG1 
cholesterol transporter gene. The disruption of the lipid rafts led to decreased 
phosphorylation of AKT and inhibition of AKT survival signalling [76]. In
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 glioblastoma LXR potentially induces cell death both in vitro and in vivo by 
decreasing LDLR protein expression and increasing ABCA1-dependent 
cholesterol efflux transporter via PI3K/AKT signalling pathway [82, 217]. 
Altogether, our findings are consistent with the previous finding and suggest 
existing multiple mechanisms behind the LXRs effect on the proliferation 
correlated to PI3K/AKT pathway. 
We next determined if the anti-proliferative effect was mediated by LXRα, 
LXRβ, or both and we took advantage of using small hairpin RNA (shRNA) and 
small interfering RNA (siRNA) techniques to knock down expression of LXRs. 
We found that LXRβ was the most potential inhibitor of the anti-proliferative 
effects of LXR. Regulation of PI3K/AKT pathway by LXR is giving us a 
potential strategy for the molecular therapy behind controlling breast cancer 
development. Beside identification of LXRβ as a potential LXR isomer 
modulates proliferation. Thus targeting approaches could be narrowed toward 
LXRβ specific agonist inhibitor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Schematic presentation of the LXR-effects on the PI3/Akt intracellular 
signalling pathway. 
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4.2 PAPER II 
Liver X Receptor (LXR) Mediates Inhibition of Estrogen Receptor Positive 
Breast Cancer Cells (MCF7) Proliferation Through mTOR-P70S6K 
Pathway 
This study is a follow up of the paper I, were we continued working on the anti-
proliferative effect of LXR on signalling pathway in MCF7 breast cancer cell 
line after treatment with synthetic agonist GW3965. In this study, we 
investigated whether inhibition of phosphorylation of mTORC1/2 was mediated 
by LXR activation. We showed that Raptor phosphorylation at Ser792 residue 
(mTORC1 component) was increased upon LXR activation, subsequently 
reduced the phosphorylation of two main regulators of mRNA translation and 
ribosome biogenesis, p70S6K and 4E-BP1, which then led to prevention of 
protein synthesis and cellular growth [218]. Interestingly, this data confirms the 
previous finding suggesting that phosphorylation of Raptor on the S792 residue 
negatively regulates mTORC1 kinase activity [219]. 
mTORC2 is another main protein kinase related to PI3K signalling pathway. 
mTORC2 together with the presence of PI3K are necessary for proper 
phosphorylation of AKT at Ser473 residue, but its upstream activator and the 
molecular mechanism that regulates its functional interaction remain elusive 
[154, 161]. We showed that phosphorylation of Rictor, an essential subunit of 
mTORC2, at Thr1135 residue was decreased by LXR activation, while mTOR 
phosphorylation at Ser2481 was slightly reduced. We speculate that this effect of 
LXR on mTORC2 might be directly related to the reduction of mTORC1 and 
p70S6K activity. This based on previous findings that show that the mTORC1 
downstream protein p70S6K positively regulates the phosphorylation of Rictor 
at T1135 residue upon growth factor stimulation. Nevertheless, Rictor 
phosphorylation at T1135 residue has no effect on mTORC2 assembly and 
kinase activity [158].  
Our work showed that phosphorylation of AKT at Ser473 residue was decreased 
upon LXR activation. Accordingly, the mechanism behind dephosphorylation of 
AKT at Ser473 residue by LXR might not be due to decreased phosphorylation 
of Rictor and mTORC2, since the dephosphorylation of AKT at Ser473 residue 
following increased expression of PHLPPL (tumor suppressor protein) has been 
shown to occur in MCF7 cell upon LXR activation [79]. 
Another key finding of this study was that the transient knockdown of mTOR, 
Rictor and Raptor using siRNA significantly affected proliferation of MCF7 
cells. We observed that the absence of mTOR blunted the inhibitory effect of 
LXR on cell proliferation. Finally, we showed that Raptor knockdown induced
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phosphorylation of mTOR at Ser2448 residue and its downstream targets of 
mTORC1, p70S6K and 4E-BP1 in the presence or absence of an LXR agonist. 
Also, LXR stimulation induced proliferation of MCF7 cells when Raptor was 
depleted. Our findings suggest the critical role of Raptor for the LXR inhibition 
of cell proliferation. Taken together, we propose that LXR may play a role in the 
modulation of breast cancer cell proliferation through PI3K/AKT/mTOR/ 
p70S6K pathway (Figure 8). Mainly, this alteration might be due to attenuation 
of mTORC1/mTORC2 subunits and their downstream targets phosphorylation. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: A model depicting the relationship between LXR, AKT and mTOR complexes. 
mTOR forms complexes with other proteins, including Raptor (forming mTORC1) or 
Rictor (forming mTORC2). Growth factor (IGF-1) signals to the PI3K/AKT pathway 
that activates mTOR function. Then, activated mTORC1 phosphorylates 4E-BP1 and 
p70S6K. AKT is pivotal for mTOR signalling, it interplays as upstream activator of 
mTORC1 and downstream effector of mTORC2. LXR negatively regulates mTOR, 
which prevents activating mTORC1, by direct phosphorylation of Raptor and their 
downstream targets S6K1 and 4E-BP1. Growth factors also increase mTORC2 activity, 
albeit the exact signalling event is unknown. Another possible mechanism for LXR 
modulation of mTORC2 activity is due to the reduction of p70S6K activity that 
positively phosphorylates Rictor at Thr1135). Also, AKT phosphorylates 
FOXO1/FOXO3a in a manner independent of mTORC2, which are inhibited by LXR.
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4.3 PAPER III 
The Effect of Liver X Receptors on Breast Cancer Tumour Progression In 
an Orthotopic Xenograft Model. 
The aim of this study was to investigate the effect of LXR activation on breast 
cancer cells in vivo. In this study we used primary tumor from a patient with 
triple negative basal-like breast cancer. Using a so-called patient-derived 
xerograph model (PDX), cells from the primary tumor were grafted into 
immuno-compromised SCID mice and allowed to expand. We show that in mice 
treated with LXR agonist GW3965 there is a significant reduction of the tumor 
progression at the dose of 40mg/kg/day compared with control. We also show 
that the expression of the proliferative marker Ki67 was reduced, further 
strengthening the antiproliferative effect of LXR activation in this model. Our 
group has previously demonstrated that synthetic LXR ligands inhibit 
proliferation also in triple negative breast cancer cell lines [78, 85]. These 
findings support the importance of LXR in triple negative breast cancers, the 
most aggressive type of breast cancer with a very poor prognostic outcome. 
Another key finding in this study is the anti-angiogenic properties of LXR 
activation. We can clearly see that the numbers of angiogenic markers (α-SMA 
positive staining and capillary density) are significantly decreased upon 
GW3965 treatment in tissue sections of the xenografts. Unfortunately, we have 
so far not found any effects of LXR activation on angiogenic genes on the 
transcriptional level. However, it has been previously shown that activation of 
LXRs reduces angiogenesis by restraining cholesterol-dependent vascular 
endothelial growth factor receptor-2 (VEGF-2) compartmentation and signalling. 
LXR agonists GW3965 and T0901317 reduced migration, tubulogenesis, and 
proliferation of human umbilical vein endothelial cells [220]. Furthermore, 
T0901317 reduced the growth of Lewis lung carcinoma grafts in mice by 
impairing angiogenesis [220]. Based on this work we need to further investigate 
the potential anti-angiogenic properties of LXR activation to elucidate if this is a 
direct effect due to LXR activation and if it can be targeted for new cancer 
therapies. We further continued to find the mechanism behind the reduced tumor 
growth by GW3965 treatment. We found that the phosphorylation status of some 
proteins in the PI3K/AKT/mTOR pathway was significantly reduced upon LXR 
activation with GW3965 compared to control group. 
The PI3K/AKT/mTOR pathway plays an important role in regulating cell 
growth, proliferation, apoptosis, angiogenesis and protein synthesis [216]. 
Reduction of phosphorylation of AKT at Ser473, p70S6K at Thr389 and 4EBP1 
at Thr70 by GW3965 further support our previous finding of the effect of LXR 
activation on the proliferation of human breast cancer cells in vitro [79]. 
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4.4 PAPER IV 
The Oxysterol Receptor LXRβ Protects Against DSS- and TNBS-Induced 
Colitis In Mice 
In this work, we examined the role of LXRs in inflammatory bowel disease 
(IBD). IBD includes ulcerative colitis and Crohn’s disease, which affects 
millions of people in the world. IBD is a major risk factor for colorectal cancer 
(CRC). In order to examine the role of LXR in colitis in mice, we used dextran 
sodium sulfate (DSS) and 2,4,6-trinitrobenzene sulfonic acid (TNBS) to induce 
colitis in mice with different genotype (wild type (WT), LXRα-/-, LXRβ-/-, 
LXRαβ-/-). WT mice were pretreated with GW3965 or vehicle by gavage, 
thereafter DSS was added to the drinking water for all genotypes. At day nine, 
the WT mice treated with DSS had lost 13% of their body weight, and a small, 
but significant, protective effect of the GW3965 treatment was observed. The 
LXR deficient mice (LXRβ-/- and LXRαβ-/-) had an earlier reduction of body 
weight, and at day seven the LXRαβ-/-, LXRα-/- and LXRβ-/- mice had lost 15%, 
2%, and 14% respectively, compared to a 5% reduction of body weight of WT 
mice. 
We observed that activation of LXRs protected mice against colitis and reduced 
the inflammation, while loss of LXRs had an opposite effect. When colitis was 
induced in LXR-deficient mice (LXRβ-/- and LXRαβ-/-), they showed a marked 
worsening of clinical symptoms including ulcers, diarrhea and rectal bleeding, 
and increased mortality in both DSS- and TNBS colitis models. Furthermore, we 
showed that loss of LXR led to increase recruitment of CD11b+ cells and 
consequently increased and prolonged release of inflammatory mediators in 
colon. Interestingly, mice treated with LXR agonist displayed faster recovery, 
increased survival, and suppressed expression of inflammatory mediators upon 
DSS-induced colitis.  
To continue investigating on the role of LXRs as anti-inflammatory factor, we 
examined human colorectal adenocarcinoma cell line Colo205 and 
SW480 pretreated with GW3965 and stimulated with tumor necrosis factor 
(TNFα) and bacterial lipopolysaccharide (LPS) to induce an inflammatory 
response.  We found that activated LXR suppressed the inflammatory response 
of both TNFα and LPS stimulation. Additionally, after depletion of LXRβ 
expression in SW480 using siRNA, we abolished the anti-inflammatory action 
of LXR. This result suggests that LXRβ is the dominant subtype responsible for 
repressing the inflammatory response in SW480 cells. Later, we used LPS to 
induce inflammatory response mediated by toll like receptor 4 (TLR4) in vivo. 
Mice pretreated with LXR ligand GW3965 and successively administrated with 
LPS intraperitonealy, showed stronger repression of inflammatory and
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chemokine genes (Tnfα, Cxcl1/Kc, Cxcl2/mip2, Ccl2/Mcp1, and Il17a) in the 
colon from LXRα-/- mice compared to LXRαβ-/- and LXRβ-/- mice. These 
findings suggest that LXRβ has a protective role in vivo in colon. Our results 
also suggest that the effect of LXRs takes place on both colonic epithelial cells 
and on resident and infiltrating immune cells in colon. By suppressing both 
inflammatory cytokine and chemokines in immune cells and colonic epithelial 
cells, thus LXRs seem to affect the immunopathogeneis of IBD at multiple 
levels. 
Finally in this paper, we studied the role of LXR in-patient with IBD and found 
that expression of both LXRα and LXRβ is suppressed in the inflamed colon 
(both Crohn’s disease and ulcerative colitis) compared with normal healthy 
colon. Thus these data confirmed the recently reported paper concerning the role 
of nuclear receptor especially LXRβ in regulation of IBD [221]. 
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5 CONCLUSIONS 
The Liver X receptor is the main focus of the present thesis. The potential anti-
proliferative and anti-inflammatory effects of LXRs and the underlying 
mechanisms of action were studied in breast cancer and inflammatory bowel 
disease, respectively. In regards to the aims, the main conclusions of this thesis 
can be summarized as follows:  
1. Inactivation of the growth factor induced PI3K/AKT intracellular signalling 
pathway by GW3965 revealed an important role for LXRs as anti-proliferative 
factor. This observation suggetes that targeting of LXR may be a potential 
strategy to controll breast cancer development (Paper I) 
 
2. Inhibition of breast cancer cell proliferation by LXRs takes place mainly 
through modulation of mTORC1 in the PI3K/AKT/mTOR signalling pathway. 
However, in order to identify the exact mechanism behind LXR regulation of 
mTORC1 and the downstream targets in breast cancer cell line remains to be 
investigated in the future. (Paper II) 
 
3. We have further identified an additional role of LXRs in the regulation of 
breast tumor growth using patient-derived xenograft model. Upon LXR 
activation with GW3965, we found a reduced tumor progression in triple 
negative breast cancer xenografts. Further investigations are needed, but the 
anti-angiogenic role of LXR remains the most important finding of our study 
and certainly opens up to the use of different drugs in combination with an 
LXR agonist to target the most aggresive forms of breast cancer. (Paper III) 
 
4. We provid evidence that LXRβ appears to have a protective role in DSS-
induced colitis in mice. Moreover, mice treated with LXR agonist display 
faster recovery, increased survival, and suppressed expression of inflammatory 
mediators upon DSS-induced colitis (Paper IV) 
      Future Perspectives                                Treska S. Hassan  
 
36 
 
6 FUTURE PERSPECTIVES 
The work of this thesis highlighted the involvement of LXR in the regulation of 
PI3K/AKT/mTOR pathway. Our novel findings add a new player that might be 
considered in the future as important therapy target candidate to inhibit cancer 
proliferation and development, in particular for breast cancer. It has been shown that 
in other types of cancer, such as prostate cancer and glioblastoma, LXR inhibits 
proliferation through regulation of lipid metabolism and that is mediated by 
PI3K/AKT signalling pathway. In this study, we added new findings to this field, 
which are the involvement of protein phosphatases and mTOR with LXRs functions. 
Nevertheless, the exact mechanisms that characterize this action have not been fully 
elucidated and more mechanistic studies are needed.  
To further study the antiangiogenic effects of LXR in PDX models we will use 
combination treatment of LXR agonist with the traditional cytostatic drugs used in 
cancer treatment. This could open a new window to investigate more about the 
therapeutic function of LXR specifically in triple negative breast cancer, but also in 
estrogen positive (ER+) breast cancer. 
 
Preliminary results: 
In ongoing study, we are trying to identify relation of LXR to the main proteins and 
phosphatases that regulate the above-mentioned PI3K/AKT/mTOR pathway. Now we 
are using CRISPR (clustered regularly interspaced short palindromic repeats) 
technology to facilitate efficient knockout of LXR genes in MCF7 breast cancer cell 
lines. By knockout of LXRs (LXRαβ-/-, LXRα-/-, LXRβ-/-) and then study their 
interactions with the main effector proteins in PI3K/AKT/mTOR pathway, we can 
identify exactly how LXRs regulate this pathway. We obtained some preliminary data 
on LXRαβ-/- by using the CRISPR technique in MCF7 cell (Figure 9). The expression 
of LXR target genes ABCA1 and ABCG1 was predominantly reduced in LXR 
deficient cells (Figure 9, A and B). Furthermore, knockout of LXRs by CRISPR 
significantly reduced the antiproliferative effect of LXR in MCF7 breast cancer 
MCF7 cells (Figure 9, C and D). These data indicate the important role of LXR in the 
proliferation of cancer cells. Clonally expanded cells are currently analyzed using 
Sanger sequencing in order to verify biallelic knockout of LXR. 
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                   A                                                                  B 
  
 
 
 
 
                   C                                                                D 
 
 
 
 
 
  
Figure 9: Knockout results of LXRαβ-/- in MCF7 cells using CRISPR technology. (A and B) 
Relative mRNA expression levels of LXR target genes ABCA1 and ABCG1. Wild type and 
LXRαβ-/- cells cultured in 1% serum medium then treated with vehicle (DMSO) or 5µM 
GW3965 for 16hrs. The data is presented as mean ±SEM, ****P< 0.0001. (C and D) Wild 
type and LXRαβ-/- cells treated with vehicle (DMSO) or 5µM GW3965 for 48hr. Cells were 
harvested after activation with 50ng/ml IGF-1 for 20 min, to perform a viability test, and the 
absolute number of viable cells was counted. The data is evaluated using ordinary one-way 
ANOVA (with Tukey test). The data is presented as means ± SEM, **p<0.01 and **** P< 
0.0001.
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